Want to join the conversation?
$BIIB 2Q15 Call: In Hemophilia, ALPROLIX revenue was $54MM and ELOCTATE revenues was $74MM. R&D expense was $491MM, or 19% of revenue. SG&A expense was $492MM or 19% of revenue. Weighted avg. diluted shares at 2Q15-end were 236MM. Revenue estimate for the rest of MS portfolio remain unchanged. OpEx as a percentage of sales remains unchanged.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.